Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
5.150
+0.260 (+5.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 18, 2025
Via
Benzinga
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
May 16, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
May 15, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Insights into Atara Biotherapeutics's Upcoming Earnings
↗
November 11, 2024
Via
Benzinga
Atara Biotherapeutics Announces Pricing of $16 Million Offering
May 15, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 06, 2025
Via
Benzinga
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
May 05, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 24, 2025
Via
Benzinga
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
March 07, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
January 27, 2025
From
The Schall Law Firm
Via
Business Wire
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
↗
January 21, 2025
FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.
Via
Benzinga
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
January 21, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates
↗
January 16, 2025
Via
Benzinga
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip
↗
January 16, 2025
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.
Via
Stocktwits
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
↗
January 16, 2025
Via
Benzinga
US Stocks Edge Lower; Retail Sales Increase Less Than Expected
↗
January 16, 2025
Via
Benzinga
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 16, 2025
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
January 14, 2025
Via
Benzinga
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
November 13, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
November 12, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Sidoti Events, LLC's Virtual November Micro-Cap Conference
November 12, 2024
Via
ACCESSWIRE
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
↗
September 04, 2024
Via
Benzinga
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
↗
September 04, 2024
Atara Biotherapeutics shares are trading higher by 20% Wednesday morning. The company announced a $36 million registered direct offering.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
